Sector Watch: Healthcare - Apr 02 2019
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $112.82 +0.91 0.81% | XBI: $91.73 +1.30 1.44% | Updated Apr 02, 2019 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| AVEO AVEO Pharmaceuticals $219.6M |
1.58+0.47 71.7 M 10.9x |
42% | ||
| EDAP52WH EDAP TMS $123.2M |
4.25+1.26 4.5 M 113.7x |
42% | ||
| SGMO Sangamo BioSciences $1.3B |
12.29+2.76 21.8 M 13.7x |
29% | ||
| ADMA ADMA Biologics Inc $234.6M |
5.06+0.99 24.3 M 42.2x |
24% | ||
| ZYNE Zynerba Pharmaceuticals $136.5M |
6.48+1.08 3.9 M 3.6x |
20% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| VIVO Meridian Bioscience $603.3M |
14.20-3.40 1.4 M 5.4x |
-19% | ||
| NLNK NewLink Genetics $65.6M |
1.76-0.29 1.5 M 2.1x |
-14% | ||
| AKBA Akebia Therapeutics $819.9M |
7.00-1.05 2.3 M 1.6x |
-13% | ||
| WBA52WL Walgreens Boots Alliance $52.2B |
55.36-8.13 34.8 M 5.2x |
-13% | ||
| CLDX Celldex Therapeutics $56.1M |
4.51-0.58 1.3 M 3.7x |
-11% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
KeyedIn Launches New Worldwide Channel Partner Program For Its PPM Solutions [globenewswire.com]Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference [globenewswire.com]
Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019 [globenewswire.com]
Meridian Bioscience Announces Preliminary Second Quarter 2019 Revenue Results; Updates Fiscal 2019 Guidance [globenewswire.com]
FDA Approves ASCENIV?, a Novel Intravenous Immune Globulin [globenewswire.com]
NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019 Nasdaq:NLNK [globenewswire.com]
EDAP TMS SA : EDAP Reports Q4 and Full Year 2018 Results [globenewswire.com]
Hematopoietic Stem Cell Transplantation - Pipeline Insight, 2019 - ResearchAndMarkets.com | Business Wire [businesswire.com]
Celldex Presents Promising Data from CDX-527 Bispecific and TAM Receptor Programs at American Association for Cancer Research (AACR) Annual Meeting 2019 [globenewswire.com]
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of UXIN, AVEO, AMR and UMC [globenewswire.com]
NACD to Explore the Future of Board Leadership [globenewswire.com]
EDAP TMS SA : University of Chicago Medicine Becomes First Hospital in the Midwest to Acquire Breakthrough Focal One® HIFU Advanced Robotic Technology for Prostate Cancer Treatment [globenewswire.com]
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LXRX, UXIN, AVEO and AMRN [globenewswire.com]
Class Action Alert CAG, DPLO & AVEO Bronstein, Gewirtz & Grossman, LLC [globenewswire.com]
ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors [globenewswire.com]
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vanda Pharmaceuticals, AVEO Pharmaceuticals, Stamps.com, and Syneos and Encourages Investors to Contact the Firm [globenewswire.com]
CLASS ACTION UPDATE for UXIN, AVEO, AMRN and AMR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [globenewswire.com]
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AVEO Pharmaceuticals, Inc. (AVEO) and Encourages AVEO Investors to Contact the Firm [globenewswire.com]
JCPenney Names Bill Wafford as Chief Financial Officer [globenewswire.com]
AVEO: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against AVEO Pharmaceuticals Inc.? AVEO - GlobeNewswire [globenewswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
